Qualifying Therapeutic Discovery Project Grants for the State of Ohio
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| ABT Holding Company (a subsidiary of Athersys Inc) | MultiStem IV to treat multiple diseases involving acute tissue damage & chronic inflammation | $ 244,479.24 | |
| ABT Holding Company (a subsidiary of Athersys, Inc) | Development of proprietary pharmaceutical products for the treatment of obesity by ABT | $ 244,479.24 | |
| ABT Holding Company (a subsidiary of Athersys, Inc) | MultiStem-LD for treatment of AMI (heart attack) and other forms of cardiovascular disease | $ 244,479.24 | |
| Airway Therapeutics | Development of Surfactant Protein-D to Prevent Occurrence of Bronchopulmonary Dysplasia | $ 1,338.50 | $ 69,736.00 |
| Akebia Therapeutics, Inc. | AKB-6548 for anemia associated with chronic kidney disease | $ 244,479.24 | |
| Akebia Therapeutics, Inc. | AKB-9778 for vascular leak | $ 244,479.24 | |
| Akebia Therapeutics, Inc. | AKB-4924 for serious infections and post-surgery wound healing | $ 216,473.50 | $ 28,005.74 |
| AnalizaDx, LLC | PSA/SIA A new test for improved diagonsis of Prostate cancer | $ 244,479.24 | |
| ApneiCare, LLC | Patient Study | $ 116,000.00 | $ 108,000.00 |
| Arteriocyte Medical Systems, Inc. | Development of Rapid, Point of Care Stem Cell Therapeutics | $ 216,663.88 | $ 27,815.36 |
| Arteriocyte, Inc | Advanced Stem Cell Based Cancer Diagnostics and Drug Discovery | $ 65,810.00 | $ 178,669.24 |
| Arteriocyte, Inc | Nanomaterials Based Production System for Therapeutic Stem Cells | $ 239,575.00 | |
| AssureRx Health, Inc. | GeneSightRx Psychiatric Pharmacogenetics Product and Clinical Development | $ 244,479.25 | |
| AtriCure, Inc | AtriClip Left Appendage Exclusion Clip Development and Associated EXCLUDE Clinical Trial | $ 244,479.25 | |
| AtriCure, Inc. | Synergy RF Ablation Development and Associated ABLATE clinical Trial | $ 244,479.25 | |
| AXIOMED SPINE CORPORATION | FREEDOM ® LIMBAR DISC | $ 244,479.25 | |
| Bionix Development Corporation | Development of a Neonatal Lighted Endotracheal tube Stylet | $ 7,020.16 | $ 59,451.79 |
| Bionix Development Corporation | Development of a Non-Contact Electrocardiogram Monitoring Pad for Infants | $ 31,172.95 | |
| Bionix Development Corporation | Development of ThermoBrachytherapy Surface applicators for Treating Cancer | $ 39,398.45 | $ 33,460.80 |
| Blue Ash Therapeutics, LLC | Azimilide-A Late Phase III Approvable Ventricular Antiarrhythmic | $ 244,479.25 | |
| CardioInsight Technologies, Inc | CardioInsight Electrocardiograph Mapping System | $ 244,479.25 | |
| Cardiox Corporation | Stroke Prevention through Development of Non-Invasive Method for Detection of Cardiac Shunts | $ 244,479.25 | |
| Cervilenz Inc | Cervilenz | $ 244,479.25 | |
| ChanRx Corporation | Vanoxerine Development | $ 76,000.00 | $ 168,479.24 |
| Checkpoint Surgical, LLC | Surgical instruments for evaluating nerve integrity | $ 244,479.25 | |
| Cleveland Medical Devices, Inc. | Movement Disorders Diagnostics | $ 44,197.00 | $ 52,573.00 |
| Consolidated Research of Richmond, Inc | Zmachine for Chronic Insomnia | $ 162,575.00 | $ 81,904.24 |
| Copernicus Therapeutics, Inc | Cystic Fibrosis Therapeutic | $ 118,458.00 | $ 126,021.25 |
| Copernicus Therapeutics, Inc | Retinitis Pigmentosa (RP) Treatment | $ 244,479.25 | |
| Copernicus Therapeutics, Inc. | Parkinson's Diseases Therapeutic | $ 28,348.00 | $ 177,412.50 |
| Dermatopathology Laboratory of Central States | Advancing molecular probes for melanoma diagnosis | $ 186,000.00 | |
| Estrocept Diagnostics, Inc | Estrocept Breast Cancer Test | $ 55,000.00 | |
| EXCMR Ltd | Exercise stress cardiac magnetic resonance imaging | $ 27,391.88 | $ 217,087.37 |
| Frantz Medical Development, Ltd. | Miniaturized Distal Vibration System for Penetrating Vascular Occlusions | $ 193,725.00 | $ 50,754.25 |
| Great Lakes Pharmaceuticals Inc | Development of B-Lock, an anti-biofilm catheter lock solution | $ 244,479.25 | |
| Imalux Corporation | Optical coherence tomography:use for preinvasive and invasive epithelial cancer | $ 244,479.24 | |
| Jagle Biopharma LLC | Formulation Development | $ 35,000.00 | |
| Juventas Therapeutics Inc | JVS-100 for Treatment of Chronic Heart Failure | $ 244,479.25 | |
| Juventas Therapeutics Inc | JVS-100 for Treatment of Critical Limb Ischemia | $ 110,013.50 | $ 134,465.75 |
| Leadscope, Inc | Creation of molecular feature-based QSAR toxicity prediction models. | $ 244,479.24 | |
| m2m Imaging Corporation | Cryogenic MRI Coil Project | $ 168,994.74 | $ 50,380.09 |
| Metallopharm LLC | Catalytic Metallodrugs | $ 51,492.50 | $ 127,000.00 |
| MetaMol Theranostics LLC | Diagnostics and Therapies for Cancer Metastasis | $ 59,767.11 | $ 38,625.00 |
| NDI Medical LLC | Therapeutic relief of post-amputation pain | $ 244,479.25 | |
| NEO PROTEOMICS, INC. | Drug development for Serotonin Receptors | $ 150,000.00 | |
| Neoprobe Corporation | Lymphoseek | $ 244,479.24 | |
| Neuros Medical, Inc | Peripheral Nerve Block Stimulation for Residual Limb Pain | $ 83,245.93 | $ 161,233.31 |
| NeuroWave Systems Inc | NeuroSENSE Monitor | $ 15,758.50 | $ 63,400.50 |
| NovelMed Therapeutics, Inc | Humanized YalcioMab for Rheumatoid Arthritis | $ 244,479.24 | |
| Optimum Therapeutics, LLC | Tumor-penetrating microparticles for treating peritoneal cancers | $ 89,823.77 | $ 65,105.67 |
| Optimum Therapeutics, LLC | Development of siRNA cancer therapeutics | $ 87,375.47 | $ 56,021.15 |
| Optimum Therapeutics, LLC | Instantaneous-release paclitaxel gelatin nanoparticles for treating superficial bladder cancer | $ 87,107.80 | $ 157,371.45 |
| Optimum Therapeutics, LLC | Clinical Development of suramin as a nontoxic chemosensitizer for treating advanced cancer | $ 157,755.83 | $ 86,723.42 |
| OtoSonics Inc. | ConfirMEE - Ear Effusion Detection and Characterization System | $ 244,479.25 | |
| Percuvision, LLC | Visually Guided Catheter | $ 244,479.25 | |
| Peritec Biosciences Ltd | Commercialization of Tissue Lined for Stent for Peripheral Arterial Disease | $ 244,479.25 | |
| PneumoSonics Inc | PneumoScan-Non-Invasive Pneumothorax Detector | $ 244,479.25 | |
| Polgenix Inc | Two Photon Opthalmascope | $ 108,557.48 | $ 42,361.15 |
| Portal Capital LLC | Prophylactic Therapies for Diseases with Airborne Transmission Vectors | $ 61,027.82 | $ 111,375.00 |
| Preciss (DBA Language Access Network, LLC) | Increasing Language Access in Clinical Environments | $ 222,413.39 | $ 22,065.86 |
| RhinoSystems Inc | Navage Nasal Hygiene Clinical Test | $ 25,000.00 | |
| Sonogage Inc | Serial Tonometer for measurement of intraocular pressure | $ 73,549.73 | $ 170,929.52 |
| Surgical Energetics, Inc | FiberSecure wound closure device | $ 50,000.00 | |
| Syncro Medical Innovations, Inc. | Development of a Tracheal Avoidance Feeding Tube with Bedside Confirmation | $ 244,479.25 | |
| Technology Medical Partners, L.L.C. | Quality of Care Management System | $ 11,433.95 | $ 93,774.17 |
| Tersus Pharmaceuticals | Commercial Development of Provinal ™ | $ 244,479.24 | |
| The Daavlin Distributing Company | Staph Therapeutic Deliverly System | $ 4,889.50 | $ 12,731.50 |
| The Utopia Group, LLC | Joey Spray Guard Delivery System | $ 88,082.69 | $ 156,396.56 |
| TheraVasc Inc. | Treatment of Peripheral Artery Disease and Diabetic Ischemic Leg Problems with TV1001 | $ 17,562.50 | $ 226,916.75 |
| Thermalin Diabetes Incorporated | Development of Next Generation Insulin Analogs - 1 | $ 11,538.39 | $ 67,582.71 |
| Thermalin Diabetes, LLC | Development of Next Generation Insulin Analogs - 2 | $ 244,479.24 | |
| Vertebration Inc | Xycor Spinal Implant for Minimally Invasive Spine Surgery | $ 244,479.25 | |
| ViewRay Incorporated | The ViewRay Renaissance™ real-time image-guided radiation therapy system | $ 244,479.25 | |
| ZIN Technologies, Inc. | Vmetrics | $ 37,370.25 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
